Acadia settles derivative suit with four-year governance overhaul, but no cash recovery

The filing confirms a settlement that was already directionally known. The court preliminarily approved the proposed settlement on August 24, 2026, so the September 11 filing mainly supplies the detailed terms and notice process rather than introducing a surprise. The underlying dispute concerns alleged misleading disclosures around the pimavanserin dementia-related psychosis application and alleged insider sales. 〔0〕

The economic cost is limited and apparently insurer-funded, but shareholders receive no cash distribution. The agreement calls for $1.5 million in attorneys’ fees and expenses, plus possible service awards of up to $5,000 per stockholder, while explicitly stating there is no common fund for shareholder claims. The stipulation says the fee will be paid by Acadia’s insurers rather than from company assets. (Settlement terms; Notice of settlement) 〔1〕

The substantive settlement is a broad governance overhaul tied directly to the old disclosure controversy. If finally approved, Acadia must maintain the reforms for at least four years, including expanded Audit Committee oversight, a four-member Scientific Committee, quarterly management reporting on trial evidence and FDA risks, a management Disclosure Committee, tighter insider-trading controls, stronger Rule 10b5-1 restrictions, and enhanced compensation clawbacks. (Exhibit A — Corporate Governance Reforms) 〔2〕

The settlement removes one layer of litigation uncertainty but does not resolve the broader legal overhang. The derivative action would be dismissed with prejudice and related books-and-records and litigation demands withdrawn after final approval, yet the related securities class action and opt-out action are expressly excluded from the release and remain pending. (Stipulation, Sections V and 10)

Net read: mixed rather than clearly positive. The filing is constructive in that it caps the derivative case, formalizes controls aimed at preventing a repeat of the alleged disclosure failures, and avoids a disclosed cash hit to Acadia itself. But it also codifies extensive governance remedies connected to allegations of deficient FDA-related disclosure and insider trading, while leaving the central securities litigation unresolved. Final approval is scheduled for January 13, 2027. (Settlement hearing)